Amanda J. Wheal
University of Nottingham
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Amanda J. Wheal.
Nature Methods | 2015
Leigh A. Stoddart; Elizabeth K. M. Johnstone; Amanda J. Wheal; Joëlle Goulding; Matthew B. Robers; Thomas Machleidt; Keith V. Wood; Stephen J. Hill; Kevin D. G. Pfleger
Bioluminescence resonance energy transfer (BRET) is a well-established method for investigating protein-protein interactions. Here we present a BRET approach to monitor ligand binding to G protein–coupled receptors (GPCRs) on the surface of living cells made possible by the use of fluorescent ligands in combination with a bioluminescent protein (NanoLuc) that can be readily expressed on the N terminus of GPCRs.
British Journal of Pharmacology | 2009
Amanda J. Wheal; T. Bennett; Michael D. Randall; Sheila M. Gardiner
In anaesthetized spontaneously hypertensive rats (SHR), there is evidence for up‐regulation of cannabinoid (CB1) receptors: antagonism of CB1 receptors causes a rise in blood pressure, and administration of the endocannabinoid, anandamide, or inhibition of anandamide degradation causes hypotension. These findings have led to the suggestion that the endocannabinoid system may be a therapeutic target in hypertension. However, since the cardiovascular responses to cannabinoids are substantially influenced by anaesthesia, the purpose of this study was to assess regional haemodynamic responses to cannabinoid receptor stimulation and inhibition in conscious SHR.
British Journal of Pharmacology | 2010
Amanda J. Wheal; S P H Alexander; Randall
Background and purpose: The endocannabinoid‐like molecule N‐oleoylethanolamine (OEA) is found in the small intestine and regulates food intake and promotes weight loss. The principal aim of the present study was to evaluate the vascular effects of OEA.
Journal of Pharmacology and Experimental Therapeutics | 2014
Amanda J. Wheal; Mariateresa Cipriano; Christopher J. Fowler; Michael D. Randall; Saoirse E O'Sullivan
Cannabidiol (CBD) decreases insulitis, inflammation, neuropathic pain, and myocardial dysfunction in preclinical models of diabetes. We recently showed that CBD also improves vasorelaxation in the Zucker diabetic fatty (ZDF) rat, and the objective of the present study was to establish the mechanisms underlying this effect. Femoral arteries from ZDF rats and ZDF lean controls were isolated, mounted on a myograph, and incubated with CBD (10 μM) or vehicle for 2 hours. Subsequent vasorelaxant responses were measured in combination with various interventions. Prostaglandin metabolites were detected using enzyme immunoassay. Direct effects of CBD on cyclooxygenase (COX) enzyme activity were measured by oxygraph assay. CBD enhanced the maximum vasorelaxation to acetylcholine (ACh) in femoral arteries from ZDF lean rats (P < 0.01) and especially ZDF rats (P < 0.0001). In ZDF arteries, this enhancement persisted after cannabinoid receptor (CB) type 1, endothelial CB, or peroxisome proliferator–activated receptor-γ antagonism but was inhibited by CB2 receptor antagonism. CBD also uncovered a vasorelaxant response to a CB2 agonist not previously observed. The CBD-enhanced ACh response was endothelium-, nitric oxide–, and hydrogen peroxide–independent. It was, however, COX-1/2– and superoxide dismutase–dependent, and CBD enhanced the activity of both purified COX-1 and COX-2. The CBD-enhanced ACh response in the arteries was inhibited by a prostanoid EP4 receptor antagonist. Prostaglandin E2 metabolite levels were below the limits of detection, but 6-keto prostaglandin F1α was decreased after CBD incubation. These data show that CBD exposure enhances the ability of arteries to relax via enhanced production of vasodilator COX-1/2–derived products acting at EP4 receptors.
European Journal of Pharmacology | 2009
Amanda J. Wheal; Michael D. Randall
The hypotensive actions of methanandamide are enhanced in anaesthetised spontaneously hypertensive rats (SHR), which may be due to increased sensory nerve activity. We have now investigated in vitro the role of sensory nerves and other vasorelaxant mechanisms of anandamide in this model of hypertension, and in rats made hypertensive by chronic inhibition of nitric oxide (NO) synthase. Male SHR and Sprague-Dawley rats (given approximately 10 mg/kg/day N(G) nitro-L-arginine methyl ester (L-NAME) to drink for 4 weeks) were used. Vasorelaxant responses to anandamide and capsaicin were determined in perfused mesenteric arterial beds and thoracic aortic rings. The contributions of sensory nerves, NO, prostanoids, cannabinoid receptors and the endothelium in these responses were investigated. In mesenteric arterial beds from SHR, anandamide was less potent as a vasorelaxant, but in aortae caused greater maximal relaxations compared to controls. The reduced potency in the mesenteric arterial bed was accompanied by impaired NO-dependent relaxation. Pre-treatment with capsaicin prevented the enhancement of vasorelaxation by anandamide in mesenteric arterial beds from rats with L-NAME-induced hypertension. The reduced potency of anandamide in mesenteric arterial beds from SHR was due to reduced NO-dependent vasorelaxation, and provides no evidence for increased sensory nerve activity. The enhanced responses in the SHR aortae were endothelium-dependent. However, in L-NAME-induced hypertension the enhanced vasorelaxation to anandamide in the mesenteric vasculature was due to increased sensory nerve-mediated activity. In conclusion, the alterations in responses to anandamide in hypertension are dependent on the vessels studied and the model of hypertension.
British Journal of Pharmacology | 2009
Amanda J. Wheal; T. Bennett; Michael D. Randall; Sheila M. Gardiner
Since the vasorelaxant potency of the endocannabinoid anandamide is enhanced in perfused mesenteric vascular beds from rats made hypertensive by chronic inhibition of NO synthase (L‐NAME in drinking water), we hypothesized that in vivo, anandamide‐induced vasodilatation would be similarly enhanced in L‐NAME‐treated animals.
European Journal of Pharmacology | 2012
Amanda J. Wheal; Stephen P.H. Alexander; Michael D. Randall
Hydrogen peroxide (H(2)O(2)) has been shown to participate in endothelium-derived hyperpolarising factor (EDHF)-mediated mechanisms. Vasorelaxation to the endocannabinoid-like N-oleoylethanolamine (OEA) and anandamide has been shown to be endothelium-dependent. Therefore, the principal aim was to investigate whether H(2)O(2) plays a role in vasorelaxation to endocannabinoids in rat mesenteric arteries. We have also investigated the effects of catalase on endothelium-dependent relaxations and vascular responses to H(2)O(2). First- (G1) and third- (G3) order branches of the superior mesenteric artery from male, Wistar rats were mounted in a wire myograph, contracted with methoxamine, and concentration-response curves to anandamide, OEA carbachol or H(2)O(2), were constructed. The influence of nitric oxide production and H(2)O(2) breakdown on these responses were then investigated using L-NAME (300 μM), and catalase (1000 Uml(-1)) respectively. In G1 mesenteric arteries, vasorelaxations to carbachol and H(2)O(2) were inhibited by L-NAME, but not by catalase. Responses to both anandamide and OEA were also unaffected by catalase. In G3 mesenteric arteries, endothelium-dependent relaxations to carbachol were modestly affected by L-NAME, unaffected by catalase alone, but their combination greatly inhibited vasorelaxation. Similarly, catalase inhibited vasorelaxation to anandamide and OEA, and combined treatment with L-NAME further reduced this response. In G1 mesenteric arteries, vasorelaxation to H(2)O(2) is predominantly mediated by nitric oxide. We conclude that in G3 arteries H(2)O(2) activity contributes towards EDHF-type responses and vasorelaxation to endocannabinoids, either directly or indirectly. Given the association between vascular pathophysiology and H(2)O(2), these findings may provide a mechanism whereby disease states may influence responses to endocannabinoid and related mediators.
Biochemical Pharmacology | 2017
Laura E. Kilpatrick; Rachel Friedman-Ohana; Diana C. Alcobia; Kristin Riching; Chloe Peach; Amanda J. Wheal; Stephen J. Briddon; Matthew B. Robers; Kris Zimmerman; Thomas Machleidt; Keith V. Wood; Jeanette Woolard; Stephen J. Hill
Graphical abstract Figure. No Caption available. Abstract Vascular endothelial growth factor (VEGF) is an important mediator of angiogenesis. Here we have used a novel stoichiometric protein‐labeling method to generate a fluorescent variant of VEGF (VEGF165a‐TMR) labeled on a single cysteine within each protomer of the antiparallel VEGF homodimer. VEGF165a‐TMR has then been used in conjunction with full length VEGFR2, tagged with the bioluminescent protein NanoLuc, to undertake a real time quantitative evaluation of VEGFR2 binding characteristics in living cells using bioluminescence resonance energy transfer (BRET). This provided quantitative information on VEGF‐VEGFR2 interactions. At longer incubation times, VEGFR2 is internalized by VEGF165a‐TMR into intracellular endosomes. This internalization can be prevented by the receptor tyrosine kinase inhibitors (RTKIs) cediranib, sorafenib, pazopanib or vandetanib. In the absence of RTKIs, the BRET signal is decreased over time as a consequence of the dissociation of agonist from the receptor in intracellular endosomes and recycling of VEGFR2 back to the plasma membrane.
European Journal of Pharmacology | 2013
Christopher P. Stanley; Amanda J. Wheal; Michael D. Randall; Saoirse E. O’Sullivan
Circulating levels of anandamide are increased in diabetes, and cannabidiol ameliorates a number of pathologies associated with diabetes. The aim of the present study was to examine how exposure to anandamide or cannabidiol might affect endothelial dysfunction associated with Zucker Diabetic Fatty rats. Age-matched Zucker Diabetic Fatty and Zucker lean rats were killed by cervical dislocation and their arteries mounted on a myograph at 37 °C. Arteries were incubated for 2h with anandamide, cannabidiol or vehicle, contracted, and cumulative concentration-response curves to acetylcholine were constructed. Anandamide (10 µM, 2h) significantly improved the vasorelaxant responses to acetylcholine in aortae and femoral arteries from Zucker Diabetic Fatty rats but not Zucker lean rats. By contrast, anandamide (1 µM, 2h) significantly blunted acetylcholine-induced vasorelaxation in third-order mesenteric arteries (G3) from Zucker Diabetic Fatty rats. Cannabidiol incubation (10 µM, 2h) improved acetylcholine responses in the arteries of Zucker Diabetic Fatty rats (aorta and femoral) and Zucker lean (aorta, femoral and G3 mesenteric), and this effect was greater in the Zucker Diabetic Fatty rat. These studies suggest that increased circulating endocannabinoids may alter vascular function both positively and negatively in type 2 diabetes, and that part of the beneficial effect of cannabidiol in diabetes may be due to improved endothelium-dependent vasorelaxation.
British Journal of Pharmacology | 2015
Joanne J. Carter; Amanda J. Wheal; Stephen J. Hill; Jeanette Woolard
Receptor tyrosine kinase inhibitors (RTKIs) targeted at VEGF receptor 2 (VEGFR2) have proved to be attractive approaches to cancer therapy based on their ability to reduce angiogenesis. Here we have undertaken a quantitative analysis of the interaction of RTKIs and two VEGF splice variants, VEGF165a and VEGF165b, with VEGFR2 by studying nuclear factor of activated T‐cells (NFAT) reporter gene activity in live HEK‐293 cells.